Literature DB >> 29676910

5'-Phosphorothiolate Dinucleotide Cap Analogues: Reagents for Messenger RNA Modification and Potent Small-Molecular Inhibitors of Decapping Enzymes.

Blazej A Wojtczak1, Pawel J Sikorski1, Kaja Fac-Dabrowska1, Anna Nowicka2, Marcin Warminski2, Dorota Kubacka2, Elzbieta Nowak3, Marcin Nowotny3, Joanna Kowalska2, Jacek Jemielity1.   

Abstract

The 5' cap consists of 7-methylguanosine (m7G) linked by a 5'-5'-triphosphate bridge to messenger RNA (mRNA) and acts as the master regulator of mRNA turnover and translation initiation in eukaryotes. Cap analogues that influence mRNA translation and turnover (either as small molecules or as part of an RNA transcript) are valuable tools for studying gene expression, which is often also of therapeutic relevance. Here, we synthesized a series of 15 dinucleotide cap (m7GpppG) analogues containing a 5'-phosphorothiolate (5'-PSL) moiety (i.e., an O-to-S substitution within the 5'-phosphoester) and studied their biological properties in the context of three major cap-binding proteins: translation initiation factor 4E (eIF4E) and two decapping enzymes, DcpS and Dcp2. While the 5'-PSL moiety was neutral or slightly stabilizing for cap interactions with eIF4E, it significantly influenced susceptibility to decapping. Replacing the γ-phosphoester with the 5'-PSL moiety (γ-PSL) prevented β-γ-pyrophosphate bond cleavage by DcpS and conferred strong inhibitory properties. Combining the γ-PSL moiety with α-PSL and β-phosphorothioate (PS) moiety afforded first cap-derived hDcpS inhibitor with low nanomolar potency. Susceptibility to Dcp2 and translational properties were studied after incorporation of the new analogues into mRNA transcripts by RNA polymerase. Transcripts containing the γ-PSL moiety were resistant to cleavage by Dcp2. Surprisingly, superior translational properties were observed for mRNAs containing the α-PSL moiety, which were Dcp2-susceptible. The overall protein expression measured in HeLa cells for this mRNA was comparable to mRNA capped with the translation augmenting β-PS analogue reported previously. Overall, our study highlights 5'-PSL as a synthetically accessible cap modification, which, depending on the substitution site, can either reduce susceptibility to decapping or confer superior translational properties on the mRNA. The 5'-PSL-analogues may find application as reagents for the preparation of efficiently expressed mRNA or for investigation of the role of decapping enzymes in mRNA processing or neuromuscular disorders associated with decapping.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29676910     DOI: 10.1021/jacs.8b02597

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  14 in total

Review 1.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

2.  Substrate-Based Design of Cytosolic Nucleotidase IIIB Inhibitors and Structural Insights into Inhibition Mechanism.

Authors:  Dorota Kubacka; Mateusz Kozarski; Marek R Baranowski; Radoslaw Wojcik; Joanna Panecka-Hofman; Dominika Strzelecka; Jerome Basquin; Jacek Jemielity; Joanna Kowalska
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-29

3.  Photocaged 5' cap analogues for optical control of mRNA translation in cells.

Authors:  Nils Klöcker; Florian P Weissenboeck; Melissa van Dülmen; Petr Špaček; Sabine Hüwel; Andrea Rentmeister
Journal:  Nat Chem       Date:  2022-06-20       Impact factor: 24.274

4.  Chemo-Enzymatic Modification of the 5' Cap Maintains Translation and Increases Immunogenic Properties of mRNA.

Authors:  Melissa van Dülmen; Nils Muthmann; Andrea Rentmeister
Journal:  Angew Chem Int Ed Engl       Date:  2021-05-06       Impact factor: 15.336

5.  Multiple covalent fluorescence labeling of eukaryotic mRNA at the poly(A) tail enhances translation and can be performed in living cells.

Authors:  Lea Anhäuser; Sabine Hüwel; Thomas Zobel; Andrea Rentmeister
Journal:  Nucleic Acids Res       Date:  2019-04-23       Impact factor: 16.971

Review 6.  Opportunities and Challenges in the Delivery of mRNA-based Vaccines.

Authors:  Abishek Wadhwa; Anas Aljabbari; Abhijeet Lokras; Camilla Foged; Aneesh Thakur
Journal:  Pharmaceutics       Date:  2020-01-28       Impact factor: 6.321

7.  Quantification of mRNA cap-modifications by means of LC-QqQ-MS.

Authors:  Nils Muthmann; Petr Špaček; Dennis Reichert; Melissa van Dülmen; Andrea Rentmeister
Journal:  Methods       Date:  2021-05-28       Impact factor: 4.647

8.  Phosphodiester modifications in mRNA poly(A) tail prevent deadenylation without compromising protein expression.

Authors:  Dominika Strzelecka; Miroslaw Smietanski; Pawel J Sikorski; Marcin Warminski; Joanna Kowalska; Jacek Jemielity
Journal:  RNA       Date:  2020-08-20       Impact factor: 4.942

9.  Evaluation of carboxyfluorescein-labeled 7-methylguanine nucleotides as probes for studying cap-binding proteins by fluorescence anisotropy.

Authors:  Anna Wojtczak; Renata Kasprzyk; Marcin Warmiński; Krystian Ubych; Dorota Kubacka; Pawel J Sikorski; Jacek Jemielity; Joanna Kowalska
Journal:  Sci Rep       Date:  2021-04-08       Impact factor: 4.379

Review 10.  Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma.

Authors:  Xiangjun Tang; Shenqi Zhang; Rui Fu; Li Zhang; Kuanming Huang; Hao Peng; Longjun Dai; Qianxue Chen
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.